新设备也有望对确认诊断和避免不必要的检查提供帮助。多家公司正加速提供便携式诊断设备和实验室结果等援助,可以帮助分析微小的血样及其他体液,从而迅速发现疾病。
Consider MelaFind, which came to market in the U.S. in 2011. The device allows dermatologists to noninvasively examine moles as deep as 2.5 millimeters beneath the surface to gauge the level of 'disorganization,' an indicator of irregular growth patterns that are a sign of melanoma, among the deadliest cancers.
以2011年进入美国市场的MelaFind为例。皮肤科医生可使用该设备无创检查在皮下深达2.5毫米处的痣,从而检测“组织破坏”的水平。“组织破坏”的水平可反应不规则生长模式,不规则生长模式是黑色素瘤等最致命癌症的迹象。
New York dermatologist Macrene Alexiades-Armenakas says she uses MelaFind to confirm that a mole is to be removed and prioritize the level of disorganization in multiple abnormal moles. In some cases, when another doctor or the patient has been concerned about a mole, MelaFind supported 'clinical diagnosis of a benign mole, thereby sparing them a biopsy,' she says.
纽约皮肤专家麦克兰纳・亚历克西亚德斯-阿门内卡斯(Macrene Alexiades-Armenakas)说,她用MelaFind证实某颗痣是否需要去除,以及对多颗异常痣的“组织破坏”水平进行排序。她说,有时候,当其他医生或病人对某颗痣表示担心时,MelaFind会支持“良性痣的临床诊断,从而让他们省去了活体组织检验的程序”。
【医患关系暧昧 怎样避免误诊】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15